Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

BIAL and WhanIn signed an Exclusive Licensing Agreement for Zebinix in South Korea
BIAL and WhanIn signed an Exclusive Licensing Agreement for Zebinix in South Korea
February 27th, 2018 - BIAL and WhanIn Pharm.
Big pharma, big data: why drugmakers want your health records
Big pharma, big data: why drugmakers want your health records
LONDON (Reuters) - Drugmakers are racing to scoop up patient health records and strike deals with technology companies as big data analytics start to unlock a trove of information about how me...
FDA approves Sorrento's non-opioid painkiller patch, shares jump
FDA approves Sorrento's non-opioid painkiller patch, shares jump
(Reuters) - Sorrento Therapeutics Inc said on Wednesday the U.
Pfizer could face £502M bill if it comes up short in U.K. patent appeal for Lyrica
Pfizer could face £502M bill if it comes up short in U.K. patent appeal for Lyrica
The U.
Party drug ketamine could prevent depression and PTSD in women, first study in female rats suggests
Party drug ketamine could prevent depression and PTSD in women, first study in female rats suggests
Ketamine could help treat stressed-related disorders, such depression and PTSD, in women, new research claims.
Today is Rare Disease Day 2018!
Today is Rare Disease Day 2018!
With events happening in over 80 countries and regions across the world, together we can raise awareness to help further the rare disease cause.
Celgene stumbles again, as FDA declines to review multiple sclerosis drug critical to company future
Celgene stumbles again, as FDA declines to review multiple sclerosis drug critical to company future
Another embarrassing and costly blunder has befallen Celgene.
Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorization in Europe for the Treatment of X–Linked Hypophosphatemia in Children
Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorization in Europe for the Treatment of X–Linked Hypophosphatemia in Children
TOKYO and LONDON and NOVATO, Calif.
First medicine to treat neonatal diabetes
First medicine to treat neonatal diabetes
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation in the European Union (EU) for ...
ARCA biopharma Reports Topline Phase 2B Results for GENETIC-AF Clinical Trial
ARCA biopharma Reports Topline Phase 2B Results for GENETIC-AF Clinical Trial
WESTMINSTER, Colo.
ObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVF
ObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVF
Geneva, Switzerland and Boston, MA - 26 February, 2018 - ObsEva SA (NASDAQ.
Watch out for this antibiotic if you have heart disease, FDA says
Watch out for this antibiotic if you have heart disease, FDA says
People with heart disease need to be careful about using the common antibiotic clarithromycin, the Food and Drug Administration said Thursday.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand